Advancing precision care
Many existing therapies for cancer and rare diseases are non-selective, impacting healthy tissue and vital organs while treating the disease. Our radiopharmaceuticals are designed to deliver focused doses of radiation with precision targeting via an injection, regardless of where the cancer or disease is in the body.
We use a radioactive isotope as a payload, attached to a targeting agent – such as a small molecule or antibody – with an affinity for targeted biomarkers on the surface of cancerous or diseased cells. Depending on the choice of radioisotope payload, either imaging or therapy can be delivered. This specificity of the targeting agent is designed to concentrate radiation at the tumour sites and to limit off-target tissue exposure.
Telix Group Companies
Telix is headquartered in Melbourne, Australia with operations in the United States, Europe (Belgium and Switzerland) and Japan.
In 2023 we opened our state-of-the-art radiopharmaceutical production facility in Belgium – one of the largest of its kind in Europe. Telix Manufacturing Solutions will deliver significant operational flexibility, research and development capabilities, and support commercial production requirements in Europe and worldwide.
Disease areas and programs
Telix’s research pipeline aims to address significant unmet medical need in urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning.
